Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 27 of 96554 for:    5

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man (Lyzme5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01634646
Recruitment Status : Terminated (Unable to recruit sufficient local qualifying volunteers for study.)
First Posted : July 6, 2012
Last Update Posted : July 16, 2013
All American Pharmaceutical
Information provided by (Responsible Party):
Jeff Golini, All American Pharmaceutical

Brief Summary:
This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels in man.

Condition or disease Intervention/treatment Phase
Overweight Elevated Cholesterol Dietary Supplement: Lyzme5 Not Applicable

Detailed Description:

Lyzme5 is a nutritional supplement, according to the Dietary Supplement Health and Education Act (DSHEA) of 1994. It is composed of B Vitamins along with a non-essential amino acid. The individual components of this supplement are individually Generally Recognized as Safe (have GRAS status). The manufacturer's objective was to create a nutritional supplement that would have the potential to positively impact body weight, and possibly one or more lipid value (i.e., total cholesterol, LDL, triglycerides)as well, in overweight individuals who may also have minimally elevated cholesterol levels.

This observational clinical study will seek to recruit 100 volunteers in order to observe whether or not the weight-loss potential of Lyzme5, previously observed earlier in three volunteers, can be duplicated within a larger group.

The second objective is to establish whether or not Lyzme5 can positively impact cholesterol levels in man.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Official Title: A Placebo-Controlled Pilot Study to Observe the Impact Lyzme5 Has on Cholesterol and Body Weight in Man
Study Start Date : May 2012
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Overweight, elevated total cholesterol
All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
Dietary Supplement: Lyzme5

Dietary Supplement (or placebo):

Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).

Week one:

A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;

Week two:

Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;

Week three through the end of the study:

Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day.

Primary Outcome Measures :
  1. Weight loss [ Time Frame: 60 days post initiation ]
    Volunteers will be weighed at the beginning and end of their 60 day participation. Weight loss (or gain) will be assessed.

Secondary Outcome Measures :
  1. Cholesterol reduction [ Time Frame: 60 days post initiation ]
    The following will be assessed at enrollment, after 30 days, and at the conclusion of the volunteer's 60 day participation: Total cholesterol, HDL, LDL, and triglyceride levels.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • At least 21 years of age or older;
  • Able to read, understanding, and signing a consent form;
  • Not pregnant or breast feeding (female only);
  • Have normal bio-markers for liver and kidney function (determined by blood test);
  • Being at least 15 lbs over your ideal weight as defined by the Body Mass Index [BMI] chart;
  • Have a total cholesterol level of or in excess of 200 mg/dl (determined by blood test);
  • Not using any illegal substances, including marijuana (medicinal or otherwise);
  • Not using any "recreational drugs"
  • Weighing less than 300 lbs

Exclusion Criteria:

  • Under 21 years of age;
  • Mentally impaired;
  • Pregnant or breast feeding;
  • A diabetic;
  • Having digestion problems;
  • Problems with kidneys, heart, or liver;
  • Having, or have had cancer;
  • Taking a prescription;
  • Weight of 300 lbs or over;
  • Total cholesterol under 200 mg/dl;
  • Using "recreational" drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01634646

Layout table for location information
United States, Montana
All American Pharmaceutical and Natural Foods Corporation
Billings, Montana, United States, 59105
Sponsors and Collaborators
Jeff Golini
All American Pharmaceutical
Layout table for investigator information
Principal Investigator: Jeff Golini All American Pharmaceutical

Layout table for additonal information
Responsible Party: Jeff Golini, President and Executive Scientist, All American Pharmaceutical Identifier: NCT01634646    
Other Study ID Numbers: Lyzme5-IRB26715/1
First Posted: July 6, 2012    Key Record Dates
Last Update Posted: July 16, 2013
Last Verified: July 2013
Keywords provided by Jeff Golini, All American Pharmaceutical:
Observational study
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Signs and Symptoms
Lipid Metabolism Disorders
Metabolic Diseases